BiotechTube
Home/Elios Therapeutics/Phillip Johnson
PJ

Phillip Johnson

Chief Financial Officer

Elios Therapeutics

Therapeutic Areas

Oncology

Elios Therapeutics Pipeline

DrugIndicationPhase
TLPO/TLPLDC VaccineHigh-risk, resected Stage III/IV Melanoma (adjuvant setting)Phase 2b

Leadership Team at Elios Therapeutics

DT
Dr. Thomas Wagner
Scientific Founder
View full Elios Therapeutics profile